logo
Plus   Neg
Share
Email

Novartis Receives Positive CHMP Opinion For Mayzent To Treat SPMS

Novartis (NVS) said that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency or EMA adopted a positive opinion for Mayzent for the treatment of adult patients with secondary progressive multiple sclerosis or SPMS with active disease evidenced by relapses or imaging features of inflammatory activity.

It is estimated that up to 80% of patients will eventually transition from relapsing remitting multiple sclerosis or RRMS to secondary progressive multiple sclerosis or SPMS.

CHMP opinion is based on the Phase III EXPAND trial, the largest randomized clinical study in a broad SPMS patient population.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
With a view to expanding its presence in France, where it has been doing business for more than 100 years, Food and beverage giant Coca-Cola Co. (KO), during the Choose France Summit, announced 1 billion euros of investments in the country over the next five years. Coca-Cola Chairman and CEO James Quincey and President Emmanuel Macron is scheduled to elaborate on the plans in September. NBCUniversal unveiled Peacock, a free premium ad-supported streaming service with subscription tiers offering more than 600 movies and 400 series. Peacock will be available on April 15 for Comcast's Xfinity X1 and Flex customers and on July 15 for the rest of the country. NBC is offering Peacock... The number of Amazon Prime members in the U.S. is growing slowly, but steadily, a recent study has shown. According to the survey by the Consumer Intelligence Research Partners, LLC or CIRP, the number of Amazon Prime members in the U.S. is estimated to have risen to 112 million in December 2019 from just over 100 million in the same period of the prior year.
Follow RTT
>